AVALO THERAPEUTICS, INC. (AVTX) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2019-09-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2019-09-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2019-09-30..
Borrowing debt
Overview →Financial period ending 2019-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2019-09-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2019-09-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2019-09-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 1.05M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 14.25M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 57.19M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2019-09-30 | (m) | (m) | $1.05M | $14.25M | (m) | (m) | $57.19M | (m) |
| 2019-06-30 | (m) | (m) | $1.05M | $14.28M | (m) | (m) | $59.62M | (m) |
| 2019-03-31 | (m) | (m) | $1.05M | $14.30M | (m) | (m) | $74.87M | (m) |
| 2018-12-31 | (m) | (m) | $1.05M | $14.33M | (m) | (m) | $70.25M | (m) |
| 2018-09-30 | (m) | (m) | $1.05M | $14.35M | (m) | (m) | $67.61M | (m) |
| 2018-06-30 | (m) | (m) | $1.05M | $14.38M | (m) | (m) | $62.15M | (m) |
| 2018-03-31 | (m) | (m) | $787.50K | $14.59M | (m) | (m) | $65.36M | (m) |
| 2017-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | (m) | $43.12M | (m) |
| 2017-09-30 | (m) | (m) | $0.00 | $0.00 | (m) | (m) | $28.20M | (m) |
| 2017-06-30 | (m) | (m) | $607.60K | $607.60K | (m) | (m) | $6.05M | (m) |
| 2017-03-31 | (m) | (m) | $1.49M | $1.49M | (m) | (m) | $3.56M | (m) |
| 2016-12-31 | (m) | (m) | $2.35M | $0.00 | (m) | (m) | $5.77M | (m) |
| 2016-09-30 | (m) | (m) | $3.19M | (m) | (m) | (m) | $9.58M | (m) |
| 2016-06-30 | (m) | (m) | $3.39M | $611.10K | (m) | (m) | $13.17M | (m) |
| 2016-03-31 | (m) | (m) | $3.30M | $1.49M | (m) | (m) | $16.93M | (m) |
| 2015-12-31 | (m) | (m) | $3.21M | $2.35M | (m) | (m) | $21.66M | (m) |
| 2015-09-30 | (m) | (m) | $3.13M | $3.20M | (m) | (m) | $5.45M | (m) |
| 2014-12-31 | (m) | (m) | $1.91M | $5.31M | (m) | (m) | $12.32M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |